Molecular diagnostics company Genedrive is set to premiere its qualitative hep-C assay at a major Asia Pacific exhibition in Singapore this week.
Having recently made first commercial sales of instruments and assays to Sysmex across the European, Middle Eastern and African markets, Genedrive inked a deal with Sysmex's Asia Pacific subsidiary to cover the Asia Pacific region, excluding India.

Genedrive's qualitative hepatitis C assay, HCV ID, provides results within 90 minutes within a decentralised testing environment. The HCD is performed on the company's portable molecular diagnostics platform, created to support the roll-out of direct-acting antivirals in low and middle-income countries.

Separately, Genedrive's HCV ID kit's first external validation study, conducted in South Africa, returned 100% specificity and sensitivity in independent use, confirming that its "good clinical validation performance can be translated into real-world settings".

As of 0845 BST, shares had declined 2.47% to 39.50p.

Related share prices
Genedrive (GDR) share price